{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:22:56Z","timestamp":1773040976318,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study systematically reviews existing data on the efficacy of Tyrosine Kinase 2 (TYK2) inhibitors in comparison to placebo or standard treatments for therapeutic benefit and improving quality of life in dermatological diseases. Seventeen records representing 13 clinical trials, one matching\u2010adjusted indirect comparison, and one case study were included. Results indicate that Deucravacitinib is superior to placebo, Apremilast and Adalimumab in treating adult patients with moderate\u2010to\u2010severe plaque psoriasis and superior to placebo in the treatment of adults with systemic lupus erythematosus. Comparative investigations on Brepocitinib and Ropsacitinib were more limited. Oral Brepocitinib demonstrated superiority over placebo in managing alopecia areata, and hidradenitis suppurativa. Topical Brepocitinib exhibited superiority over placebo in treating atopic dermatitis, but not plaque psoriasis. Ropsacitinib demonstrated superiority over placebo in the management of plaque psoriasis. Brepocitinib and Ropsacitinib had more side effects than Deucravacitinib.<\/jats:p>","DOI":"10.1111\/ajd.14391","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:32:54Z","timestamp":1733481174000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A systematic review of the efficacy of <scp>TYK2<\/scp> inhibitors in patients with dermatological disease"],"prefix":"10.1111","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2047-9536","authenticated-orcid":false,"given":"Malindi Georgia","family":"Haggett","sequence":"first","affiliation":[{"name":"Department of Dermatology The Royal Children's Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangho","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology Monash Medical Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis Yi Xing","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Dermatology Skin Health Institute  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/ddg.14585","article-title":"TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases","volume":"19","author":"Ghoreschi K","year":"2021","journal-title":"JDDG"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043391"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01261-8"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104840"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S380686"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01082-y"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10777-w"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15605"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab135"},{"key":"e_1_2_8_13_1","unstructured":"SquibbB\u2010M ClinicalTrial.gov.An investigational study to evaluate experimental medication BMS\u2010986165 in Japanese participants with moderate\u2010to\u2010severe psoriasis.2019. Available from:https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03924427"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16740"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_8_17_1","unstructured":"SquibbB\u2010M clinicaltrails.gov.An investigational study to evaluate experimental medication BMS\u2010986165 compared to placebo in participants with plaque psoriasis (POETYK\u2010PSO\u20103) in Mainland China Taiwan and South Korea (POETYK\u2010PSO\u20103).2019Available from:https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04167462"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00649-y"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00977-1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.07.030"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1046"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.03.962"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad098"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21826"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.059"},{"key":"e_1_2_8_29_1","unstructured":"Pfizer ClinicalTrials.gov.A study to evaluate the safety and efficacy of PF\u201006650833 PF\u201006700841 and PF 06826647 in adults With Hidradenitis Suppurativa.2019Available from:https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04092452"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7539"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2018.017"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12267"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.14391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T16:53:08Z","timestamp":1739465588000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.14391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/ajd.14391"],"URL":"https:\/\/doi.org\/10.1111\/ajd.14391","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"2024-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}